Adding anifrolumab to standard treatment for systemic lupus erythematosus led to faster achievement of low disease activity ...

After being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest it could help to end a drought in treatments for autoimmune disease systemic ...

AstraZeneca has, however, held on to anifrolumab, a late-stage phase 3 candidate being developed for the severe autoimmune disease lupus. "Autoimmune diseases represent one of the largest unmet ...

Potential therapeutic targets to address monocyte and macrophage involvement in IIMs include anti-CCR2, anti-GM-CSF, anti-CSF-1R, Nrf2 activators, PPAR-γ agonists, mesenchymal stem cell-derived ...

AstraZeneca investing $2.5 billion in China as drugmaker seeks to recover from scandals AstraZeneca said on Friday it will spend $2.5 billion on a research and development hub in Beijing, as the ...

So, that's exciting news. The anifrolumab trial is moving along nicely. And so we might know soon, whether or not we might have an anti-interferon agent available for the treatment of lupus nephritis.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

AstraZeneca Pharma India Ltd., incorporated in the year 1979, is a Mid Cap company (having a market cap of Rs 21,277.00 Crore) operating in Pharmaceuticals sector. AstraZeneca Pharma India Ltd. key ...

At close: 5:29:52 PM GMT+1 Loading Chart for AZN.ST ...